Q2 2026 Ironwood Pharmaceuticals Inc Earnings Call Transcript
Key Points
- LINZESS delivered strong Q2 2026 performance with U.S. net sales of $282.3 million, a 14% year-over-year increase, driven by both demand growth and improved net price.
- The company raised its full-year 2026 guidance for LINZESS U.S. net sales to between $1.15 billion and $1.2 billion, representing a greater than 30% year-over-year increase and the highest annual sales in the product's history.
- FDA approval of LINZESS for functional constipation in pediatric patients two years of age and older expands the product's reach to a new patient population, addressing an unmet need.
- Apraglutide's Phase III STARS trial demonstrated significant reductions in parenteral support requirements, with more than one in five patients achieving enteral autonomy in the long-term extension study, positioning it as a potential best-in-class therapy.
- The company generated strong financial results with $51.3 million in GAAP net income and $83 million in adjusted EBITDA, and repaid its $200 million convertible notes at maturity, strengthening its balance sheet.
- The company expects to end 2026 with gross leverage below 1X, further enhancing financial flexibility to support apraglutide's development and commercialization.
- The company noted potential demand softening in Medicaid due to the elimination of inflationary rebates, although it has worked to mitigate this risk and currently expects mid-single-digit demand growth.
- The STARS II trial is still in early stages, with enrollment just beginning, and there is uncertainty regarding the timeline for completing the trial and potential delays in site activation.
- The company acknowledged a previous dosing error in the STARS trial (delivering 3.5 mg instead of 5 mg), which required root cause analysis and kit improvements, and there is a risk of similar issues in STARS II.
- R&D expenses are expected to increase in the second half of 2026 due to the ramp-up of STARS II, which could impact profitability despite strong current results.
- The company faces potential variability in gross-to-net rebate reserves, although it expects more consistent net pricing across channels this year.
- The company's guidance relies on continued mid-single-digit demand growth, which may be affected by seasonal factors and payer dynamics, posing a risk to achieving the higher end of the range.
Good morning, everyone. My name is Ian and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q2 2026 Investor Update Conference Call.
(Operator Instructions)
I would like to now turn the call over to Chris Stamm, VP, Investor Relations and Communications.
Good morning and thanks for joining our second quarter 2026 investor update. A press release issued this morning highlighting Q2 results can be found on our website.
Today's call and accompanying slides include forward-looking statements within the meetings of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties. That may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current Safe Harbor Statement slide, as well as under the heading Risk Factors in our Annual Report Form 10-K for the year
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
